The Tanner Pharma Group announced on Tuesday that the company would be increasing the European supply of Leukine—a drug used to treat radiation sickness—amid renewed threats of nuclear conflict as a result of Russia’s ongoing war in Ukraine. In a statement released on March 24, the Tanner Pharma Group said it was expanding the availability of Leukine throughout Europe in collaboration with Partner Therapeutics (which owns the patent for Leukine). “In response to the ongoing conflict in Ukraine, Tanner is supporting preparedness and response in Europe by increasing the local inventory of Leukine that can be rapidly deployed in response to an emergency,” said Banks Bourne, CEO and founder of Tanner Pharma. Leukine, a drug commonly used in the treatment of cancer patients, was approved by the FDA in 2018 to treat Acute Radiation Syndrome, the scientific name of the condition more commonly known as radiation sickness. “Leukine was shown …